ALAFY Fundamental Analysis - AFYREN SAS

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ALAFY. ALAFY was compared to 70 industry peers in the Chemicals industry. No worries on liquidiy or solvency for ALAFY as it has an excellent financial health rating, but there are worries on the profitability. ALAFY is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALAFY had negative earnings in the past year.

ALAFY had a negative operating cash flow in the past year.

In the past 5 years ALAFY always reported negative net income.

ALAFY had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ALAFY (-22.25%) is worse than 87.67% of its industry peers.

The Return On Equity of ALAFY (-24.67%) is worse than 84.93% of its industry peers.

		Industry Rank	Sector Rank
ROA	-22.25%
ROE	-24.67%
ROIC	N/A

ROA(3y)-13.69%

ROA(5y)-10.18%

ROE(3y)-15.61%

ROE(5y)-12.47%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 89.71%, ALAFY belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

In the last couple of years the Gross Margin of ALAFY has declined.

ALAFY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	89.71%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.47%

GM growth 5Y-1.95%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALAFY does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALAFY has about the same amount of shares outstanding.

The number of shares outstanding for ALAFY has been increased compared to 5 years ago.

Compared to 1 year ago, ALAFY has an improved debt to assets ratio.

2.2 Solvency

ALAFY has an Altman-Z score of 9.58. This indicates that ALAFY is financially healthy and has little risk of bankruptcy at the moment.

ALAFY has a Altman-Z score of 9.58. This is amongst the best in the industry. ALAFY outperforms 98.63% of its industry peers.

ALAFY has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.

With an excellent Debt to Equity ratio value of 0.03, ALAFY belongs to the best of the industry, outperforming 93.15% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	9.58

ROIC/WACCN/A

WACC7.82%

2.3 Liquidity

ALAFY has a Current Ratio of 14.74. This indicates that ALAFY is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of ALAFY (14.74) is better than 100.00% of its industry peers.

A Quick Ratio of 14.74 indicates that ALAFY has no problem at all paying its short term obligations.

The Quick ratio of ALAFY (14.74) is better than 100.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	14.74
Quick Ratio	14.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALAFY have decreased strongly by -18.92% in the last year.

The Revenue has decreased by -3.05% in the past year.

ALAFY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.31% yearly.

EPS 1Y (TTM)-18.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-35%

Revenue 1Y (TTM)-3.05%

Revenue growth 3Y-1.95%

Revenue growth 5Y4.31%

Sales Q2Q%-11.73%

3.2 Future

ALAFY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.04% yearly.

The Revenue is expected to grow by 92.86% on average over the next years. This is a very strong growth

EPS Next Y17.78%

EPS Next 2Y14.5%

EPS Next 3Y13.04%

EPS Next 5YN/A

Revenue Next Year-5.8%

Revenue Next 2Y-2.94%

Revenue Next 3Y92.86%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALAFY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALAFY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ALAFY's earnings are expected to grow with 13.04% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y14.5%

EPS Next 3Y13.04%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALAFY!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

AFYREN SAS

EPA:ALAFY (12/12/2025, 7:00:00 PM)

2.5

-0.16 (-6.02%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners8.98%

Inst Owner ChangeN/A

Ins Owners7.81%

Ins Owner ChangeN/A

Market Cap89.22M

Revenue(TTM)2.70M

Net Income(TTM)-11.35M

Analysts86

Price Target5.1 (104%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-3.85%

PT rev (3m)-3.85%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)26.73%

EPS NY rev (3m)26.73%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	33.02
P/FCF	N/A
P/OCF	N/A
P/B	1.95
P/tB	2.08
EV/EBITDA	N/A

EPS(TTM)-0.44

EYN/A

EPS(NY)-0.32

Fwd EYN/A

FCF(TTM)-0.15

FCFYN/A

OCF(TTM)-0.14

OCFYN/A

SpS0.08

BVpS1.28

TBVpS1.2

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-22.25%
ROE	-24.67%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	89.71%
FCFM	N/A

ROA(3y)-13.69%

ROA(5y)-10.18%

ROE(3y)-15.61%

ROE(5y)-12.47%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.47%

GM growth 5Y-1.95%

F-Score5

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	31.4%
Cap/Sales	9.99%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	14.74
Quick Ratio	14.74
Altman-Z	9.58

F-Score5

WACC7.82%

ROIC/WACCN/A

Cap/Depr(3y)59.81%

Cap/Depr(5y)64.73%

Cap/Sales(3y)13.21%

Cap/Sales(5y)12.63%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-18.92%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-35%

EPS Next Y17.78%

EPS Next 2Y14.5%

EPS Next 3Y13.04%

EPS Next 5YN/A

Revenue 1Y (TTM)-3.05%

Revenue growth 3Y-1.95%

Revenue growth 5Y4.31%

Sales Q2Q%-11.73%

Revenue Next Year-5.8%

Revenue Next 2Y-2.94%

Revenue Next 3Y92.86%

Revenue Next 5YN/A

EBIT growth 1Y4.52%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year50.45%

EBIT Next 3Y13.43%

EBIT Next 5YN/A

FCF growth 1Y-10.76%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-21.16%

OCF growth 3YN/A

OCF growth 5YN/A

AFYREN SAS / ALAFY.PA FAQ

Can you provide the ChartMill fundamental rating for AFYREN SAS?

ChartMill assigns a fundamental rating of 3 / 10 to ALAFY.PA.

What is the valuation status of AFYREN SAS (ALAFY.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to AFYREN SAS (ALAFY.PA). This can be considered as Overvalued.

Can you provide the profitability details for AFYREN SAS?

AFYREN SAS (ALAFY.PA) has a profitability rating of 1 / 10.

How financially healthy is AFYREN SAS?

The financial health rating of AFYREN SAS (ALAFY.PA) is 6 / 10.

AFYREN SAS (ALAFY.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AFYREN SAS / ALAFY.PA FAQ

Can you provide the ChartMill fundamental rating for AFYREN SAS?

What is the valuation status of AFYREN SAS (ALAFY.PA) stock?

Can you provide the profitability details for AFYREN SAS?

How financially healthy is AFYREN SAS?